MAPKAPK2 and head and neck squamous cell carcinoma: We have previously demonstrated that MK2 activation in HNSCC contributes to radiotherapy resistance and high MK2 phosphorylation in p16-negative oropharyngeal HNSCC patients was a poor prognostic feature associated with significantly worse disease specific survival compared to patients with low MK2 phosphorylation.